Home » Stocks » Calliditas Therapeutics

Calliditas Therapeutics AB (CALT)

Stock Price: $23.80 USD -1.00 (-4.03%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 592.98M
Revenue (ttm) 21.13M
Net Income (ttm) -3.73M
Shares Out 24.92M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $23.80
Previous Close $24.80
Change ($) -1.00
Change (%) -4.03%
Day's Open 24.73
Day's Range 23.59 - 25.91
Day's Volume 22,111
52-Week Range 19.00 - 28.38

More Stats

Market Cap 592.98M
Enterprise Value 506.82M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.92M
Float 24.34M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -0.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,798
Short Ratio 1.13
Short % of Float 0.00%
Beta 1.19
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 28.06
PB Ratio 3.82
Revenue 21.13M
Operating Income -3.20M
Net Income -3.73M
Free Cash Flow -8.13M
Net Cash 86.17M
Net Cash / Share 3.46
Gross Margin 100.00%
Operating Margin -15.16%
Profit Margin -17.60%
FCF Margin -38.48%
ROA -11.94%
ROE -19.02%
ROIC 938.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$45.34*
(90.50% upside)
Low
37.6
Current: $23.80
High
56.0
Target: 45.34
*Average 12-month USD price target from 5 stock analysts.

Financial Performance

Financial numbers in millions SEK.

Financial Overview

Year20192018
Revenue185-
Gross Profit185-
Operating Income-28.02-132
Net Income-32.58-132
Shares Outstanding46.30-
Earnings Per Share-1.76-10.18
Operating Cash Flow-71.01-128
Capital Expenditures-0.12-
Free Cash Flow-71.13-128
Cash & Equivalents754646
Net Cash / Debt754646
Assets845648
Liabilities57.1330.24
Book Value788618
Numbers in millions SEK, except per-share numbers.

Company Profile

Company Details

Full Name Calliditas Therapeutics AB
Country Sweden
Employees 21
CEO Renée Julie Elisabet Aguiar-Lucander

Stock Information

Ticker Symbol CALT
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: CALT
IPO Date June 5, 2020

Description

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden. Address: Kungsbron 1, C8, Stockholm, Sweden, 111 22